Array BioPharma Announces Clinical Data Presentations at the 2012 ASCO Annual Meeting

BOULDER, Colo.--(BUSINESS WIRE)--May 16, 2012 - Array BioPharma Inc. (NASDAQ: ARRY) today announced oral presentations on its two MEK inhibitors, selumetinib (AZD6244) and MEK162 at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting, which will held June 1-5, 2012 at McCormick Place in Chicago, Illinois. Array invented selumetinib and MEK162 and subsequently licensed them to AstraZeneca and Novartis, respectively.

Three oral presentations at ASCO:
Selumetinib

Title:

 

          Phase II double-blind, randomized study of selumetinib (SEL) plus docetaxel (DOC) versus DOC plus placebo as second-line treatment for advanced KRAS mutant non-small cell lung cancer (NSCLC) (Abstract #7503)

 

Presenter:

 

          Pasi A. Janne, MD, PhD
Date:

 

          Monday, June 4, 2012, 5:00 – 5:15 p.m. EDT
 
Title:

 

          Reacquisition of RAI uptake in RAI-refractory metastatic thyroid cancers by pretreatment with the MEK inhibitor selumetinib (Abstract #5509)

 

Presenter:

 

          Alan L. Ho, MD, PhD
Date:

 

          Monday, June 4, 2012, 1:00 – 1:15 p.m. EDT
 
MEK162

 

           
Title:

 

          Efficacy and safety of oral MEK162 in patients with locally advanced and unresectable or metastatic cutaneous melanoma harboring BRAFV600 or NRAS mutations* (Abstract #8511)

 

 

Presenter:

 

          Paolo A. Ascierto, MD
Date:

 

          Monday, June 4, 2012, 4:45 – 5:00 p.m. EDT
             
The abstracts can be accessed through the ASCO website, http://abstract.asco.org/. After June 4, 2012, the oral presentation slides will be available as PDFs on Array's website at www.arraybiopharma.com.

 

he abstract submitted for MEK162 does not incorporate data and new 
      findings generated since the time of submission in early 2012. The 
      latest and most up-to-date clinical data will be delivered during the 
      investigator's presentation at the Annual Meeting itself, at the date 
      and time listed above.
    
In addition, the following scientific posters on selumetinib and GDC-0068, an Akt inhibitor partnered with Genentech, will be presented at the conference.
ASCO
Abstract
Number

 

        ASCO Abstract Title         Presentation Date
and Time (EDT)

 

3529         Pharmacodynamic biomarker-driven trial of MK-2206, an AKT inhibitor, with AZD6244 (selumetinib), a MEK inhibitor, in patients with advanced colorectal carcinoma (CRC)         Friday, June 1
2 - 6 pm

 

3020         A phase I, single-institution, open-label, dose escalation trial with an expansion cohort evaluating the safety and tolerability of AZD6244 and IMC-A12 in subjects with advanced solid malignancies         Saturday, June 2
2:15 - 6:15 pm

 

3021         A phase Ib study of the Akt inhibitor GDC-0068 with docetaxel (D) or mFOLFOX-6 (F) in patients (pts) with advanced solid tumors         Saturday, June 2
2:15 – 6:15 pm

 

8598         Pharmacodynamic activity of selumetinib to predict radiographic response in advanced uveal melanoma         Sunday, June 3
9 am - 1 pm

 

3103         A phase I study of selumetinib (AZD6244/ARRY-142866) in combination with cetuximab (cet) in refractory solid tumors and KRAS mutant colorectal cancer (CRC)         Monday, June 4
9 am - 1 pm

 

4100         A phase I/II study of AZD6244 in combination with sorafenib (Nexavar - Bayer/Onyx) in advanced hepatocellular carcinoma         Monday, June 4
9 am - 1 pm

 

TPS2616         A phase Ib/II study testing the safety and efficacy of combined inhibition of the AKT/PI3K and AR signaling pathways in castration-resistant prostate cancer: GDC-0068 or GDC-0980 with abiraterone acetate versus abiraterone acetate         Monday, June 4
9 am - 1 pm

 

6582         Phase II study of the oral MEK inhibitor selumetinib (AZD6244) in advanced acute myeloid leukemia (AML)         Monday, June 4
2:15 - 6:15 pm

 

                     
About Array BioPharma

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small-molecule drugs to treat patients afflicted with cancer and inflammatory diseases. Array has four core proprietary clinical programs: ARRY-614 for myelodysplastic syndromes, ARRY-520 for multiple myeloma, ARRY-797 for pain and ARRY-502 for asthma. In addition, Array has 10 partner-funded clinical programs including two MEK inhibitors in Phase 2: selumetinib with AstraZeneca and MEK162 with Novartis. For more formation on Array, please go to www.arraybiopharma.com.

 

Contact: Array BioPharma Inc.
Tricia Haugeto, 303-386-1193
thaugeto@arraybiopharma.com

 

 

Posted: May 2012

View comments

Hide
(web3)